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ABSTRACT:
Over the past decades numerous markers of the tumor burden have been discovered 
in chronic lymphocytic leukemia (CLL). Among these, the microRNAs seem to have 
a promising role. The development and validation of miRNAs as biomarkers should 
have significant impact in improving early cancer detection and diagnosis, enhancing 
therapeutic success, and increasing the life expectancy of patients. We identified miR-
181b as a biomarker for the progression of this disease from indolent to aggressive.  
For this study we used sequential samples from patients with either progressive 
or stable course of the illness. Here, we discuss more extensively this issue by 
adding novel findings and introducing a novel approach for monitoring CLL patients.
INTRODUCTION
B-Chronic lymphocytic leukemia (CLL) is a 
monoclonal disorder characterized by a progressive 
accumulation of functionally incompetent B lymphocytes 
expressing on their surface CD5 and CD19 antigens. 
Based on cases diagnosed in 2004-2008 from 17 SEER 
geographic areas, the age-adjusted incidence rate was 
4.2 per 100,000 men and women per year with the 
median age at diagnosis of 72 years ( http://seer.cancer.
gov/). The clinical course of CLL is highly variable 
and approximately one third of patients never requires 
treatment and die, from causes unrelated to CLL; in 
another third an initial indolent phase is followed by 
progression of the disease; and the remaining third has 
aggressive disease at the outset and needs immediate 
treatment. The traditional staging systems for CLL, Rai 
in the United States and Binet in Europe, are very good at 
identifying whom to treat at the time of diagnosis but not 
at identifying who will later need treatment [1]. Clinical 
trials have shown that treating early-stage CLL with 
chlorambucil offers no benefit over delaying treatment 
until the disease progresses [2]. Albeit the results of this 
study there is consensus that most patients stage I or II 
disease that is progressive, should be considered for early 
treatment [3]. On these basis, over the past few year a 
number of monotherapies have been explored as the 
frontline therapy of patients with CLL, without a robust 
improvement in terms of  Progression-Free-Survival (PFS) 
[4-8]. However, the development of more active therapies 
could rekindle interest in studying the benefit of early 
treatment for selected patients with CLL[9, 10]. New trials 
are ongoing to validate whether patients at the early stage 
can benefit of early intervention (clinicaltrial.gov).In this 
context the discovery of biomarker of disease progression 
could be extremely useful to manage patients at the early 
stage. 
To date numerous biological markers of tumor 
burden and predictive have been identified (some of them 
reviewed in [11]) but only few are currently used in the 
standard management of CLL patients. These include 
IGHV mutational status, ZAP-70 and CD38 expression 
levels on gated CD19/CD5 cells, FISH analysis. All of 
those are markers at the diagnosis: IGVH and ZAP-70 are 
stable while controversy has developed regarding whether 
CD38 expression can vary over the course of disease [12]. 
FISH analysis in the current clinical practice is performed 
only on new diagnosed patients and can vary or not over 
time, albeit increased abnormal genetic complexity is 
associated with advanced stages.Oncotarget 2012; 3:  195-202 196 www.impactjournals.com/oncotarget
State-of- the-Art on microRNA as potential 
biomarkers in CLL
Over the past few years a new class of small genes, 
miRNAs, have demonstrated to be potential biomarkers 
of cancer. Increasing experimental evidences have 
supported the idea of aberrant miRNA expression is 
involved in cancer pathogenesis[13]. In this section we 
will give an overview on the role of miRNAs as diagnostic 
and prognostic tools focusing on chronic lymphocytic 
leukemia.
Ever  since  the  first  association  of  miRNAs  with 
cancer by Calin et. al[14], it was clear that these genes 
could play an important role in the clinical management 
of cancer patients. In this study the down-regulation of 
the expression of the miR-15a/16-1 cluster located at the 
chromosome region 13q14, which is frequently deleted in 
B cell chronic lymphocytic leukemia, was correlated with 
13q14 deletion as sole abnormality, thereby with a good 
prognosis. Subsequently, microarray technologies served 
as powerful tools to analyze the expression of hundreds 
of miRNAs and to recognize microRNAs CLL-related. A 
signature of 25 miRNAs was identified  to discriminate 
CLL cells versus CD5+ normal B cells [15]. MiRNAs 
could also be seen as prognostic indicators in CLL[16]. By 
correlating the conventional prognostic markers (IGHV 
mutation status and/or ZAP-70 expression) with global 
miRNAs expression were identified 13 genes differentially 
expressed between CLL cells expressing either  unmutated 
IGHV/ ZAP70+ or mutated IGHV/ZAP70-. This signature 
included miR- 15a, miR-195, miR-221, miR-23b, miR-
155, miR-223, miR29a-2, miR- 24-1, miR-29b-2, miR-
146, miR-16-1, miR-16-2, and miR-29c. Six of those 
were also predicting the time-to-treatment, establishing so 
the first microRNA signature associated with prognosis in 
CLL. Subsequently other studies partially confirmed those 
data, probably due to the different approach or a different 
control used to identify miRNAs differentially expressed 
[17] [18]. Stamatopoulos et al widen the investigation by 
considering the prognostic relevance of miR-29c and miR-
223 related to multiple parameters (Binet staging, soluble 
CD23,  β2-microglobulin,  lymphocyte  doubling  time, 
IGVH status, ZAP70, LPL and cytogenetic abnormalities). 
Two consequently studies by the same authors showed 
that the low expression of miR-29c and the miR-223 is 
associated with the progression from Binet stage A to C; 
both miRNAs could predict treatment-free survival but 
only miR-29c can significantly predict the overall survival 
[19, 20]. This microRNA was also described to have a 
functional role in indolent CLL[21].
Focusing on another prognostic parameter, the 
cytogenetics, we conducted miRNA analysis in a cohort 
of 61 patients with CLL cells carrying several distinct 
karyotypes (trisomy 12, 13q deletion, 11q deletion, 17p 
deletion and normal karyotype) [22]. We identified 32 
microRNAs able to discriminate the 11q deletion, 17p 
deletion, trisomy 12, 13q deletion, and normal karyotype 
cytogenetic subgroups. MiRNAs were also able to stratify 
aggressive from indolent form of the disease among 
patients with CLL cells harboring the 17p deletion (miR-
181 family, miR-223, and miR-29b/c). With the same 
intent, Rossi et al analyzed miRNAs expression in CLL 
cases with chromosome 17p deletion and CLLs with 
normal 17p and normal karyotype. They found miR-21 
expression levels predicting the overall survival and miR-
181b expression levels predicting treatment-free survival 
[23]. Recently Moussay et al. looked at the  microRNA 
expression profile in the  plasma of CLL patient rather 
than CLL cells [24]. They found that certain extracellular 
circulating miRNAs in patients with CLL are present at 
levels significantly different compared to healthy donors 
and that some of them are differentially expressed between 
ZAP70+ and ZAP70- expressing CLL cells. The combined 
plasma level of miR-29a, miR-483-5p, miR-195, miR-
185, miR-135a* and miR-15a could stratifies ZAP70+ 
from ZAP70- expressing CLL cells. They also showed 
that miR-20a in plasma correlates with the severity of the 
disease.
A different approach finalized to identify predictive 
markers of the drug resistance in CLL was conducted by 
Ferracin et al. who analyzed the expression of miRNAs in 
CLL cells from 17 patients receiving fludarabine mono-
therapy. The cells were taken from patients before and 5 
days after fludarabine treatment [25]. By whole genome 
expression  analysis  they  confirmed  the  defect  of  P53 
pathway in the fludarabine-refractory CLL, previously 
published by Zenz et al [26], although contrarily to that 
study, they did not find a significant differential expression 
of miR-34a between responder and refractory cases to 
fludarabine  treatment  in  their  cohort.  Instead  miR-21, 
miR-222 and miR-148a expression were able to predict 
response to therapy with an accuracy of 80% in the 
training set and 100% in an independent validation set.
All these miRNAs are proposed as biomarkers in this 
disease and have been identified by comparing groups of 
patients classified on the basis of other well-established 
prognostic markers. However, we believe that a 
retrospective study in which the patients have been studied 
in a time frame during which their illness developed a 
different outcome, could provide important information 
in discovering  the markers for the progression of CLL.
Mir-181b expression for monitoring the clinical 
progression of chronic lymphocytic leukemia 
In the attempt to search for reliable markers of the 
progression of this disorder we compared the microRNA 
profile  expression  of  sequential  PBMC  samples  from 
23 patients with a progressive disease [22]. The two 
sequential samples were chosen so that the last time point 
is a more aggressive form as compared to its previous Oncotarget 2012; 3:  195-202 197 www.impactjournals.com/oncotarget
counterpart  (parameters  defined  according  to  Hallek 
et al.[27]). By array technologies we identified several 
miRNAs differentially expressed between coupled 
samples. 
Then our study was focused on the  most significant 
differentially expressed, miR-181b, although other 
interesting miRNAs were also found. Here, we show the 
technical validation by qRT-PCR of miR-126*, miR-223, 
Figure 1: Expression values of miR-126*, miR-130a, miR-130b and miR-223 in sequential samples from patients with 
progressive disease(training set). Relative expression of the mature miRNAs, in the first time point (dark blocks) and last time point 
(clear blocks) from sequential samples of CLL patients with progressive  disease. The expression has been determined by stem-loop qRT-
PCR. Each sample data was normalized to the endogenous reference RNU44 by using 2-∆ct method. P value is the result of the paired ttest Oncotarget 2012; 3:  195-202 198 www.impactjournals.com/oncotarget
miR-130a and miR-130b (Fig. 1). The expression of miR-
181a was also analyzed on the same set of samples because 
it is in the same cluster with miR-181b on chromosome 1 
(miR-181a-1 and miR-181b-1) and chromosome 9 (miR-
181a-2 and miR-181b-2). MiR-181a shows a similar 
course as compared to miR-181b (Fig.2) albeit it did not 
appear in our analysis because of its very low  expression, 
thereby excluded by the data analysis. We observed 
that all these miRNAs significantly decrease during the 
progression of CLL; however only miR-181b was further 
examined on samples from patients with a stable disease 
and  on a validation set of 78 patients including patients 
with either progressive or stable disease [28].
We found that miR-181b expression value decreased 
over the progression of the disease while its expression 
remained unchanged in patients with a stable course of the 
disease, all the patients were observed for a comparable 
time. We validated this result in an independent cohort 
of samples in which the criteria for defining the form of 
the disease matched those of the training set with the only 
exception of the WBC (white blood cell). In this cohort not 
all the patients with a progressive disease  had increasing 
lymphocytosis. We observed decreased expression of the 
miR-181b over time also in those cases, suggesting that 
changes in expression levels of  the miR-181b occurred 
independent of increases in white blood cell counts.   
Looking closely at the expression value of the miR-181b 
in sequential samples from a few patients, we observed 
that not always there is a linear reduction over time. We 
observed slight fluctuations; thereby we used a decrease 
of 50% or more in miR-181b levels as the threshold to 
mitigate potential problems caused by small fluctuations 
in miR expression in any one sample due to technical or 
biologic variation. Also, we used the value of ≤ 0.005 at 
the first time point as cutoff to indicate patients with a 
progressive status. This value represents the expression 
level of miR-181b normalized on the RNU44 expression 
level and was chosen as threshold because it was frequent 
only in samples from patients with a progressive disease. 
These two parameters, decrease of 50% or more 
between sequential samples and value of ≤ 0.005 at the 
first time point, were defined  as properties and associated 
with the clinical outcome.  Kaplan-Meier curves show 
that  a requirement for treatment is clearly associated with 
decline of miR-181b expression, thereby patients having 
the properties more likely  experience treatment.   Other 
prognostic markers, such as IGVH mutational status 
and ZAP-70 expression also stratify patients requiring 
treatment [29] [30], thus, what is the added value of miR-
181b to the current biomarkers? 
To answer this question, we analyzed, among the 
patients with progressive disease included in both training 
and validation sets, how well the expression of miR-
181b could identify patients with progressive/aggressive 
disease relative to that of other well-established prognostic 
markers (e.g. CLL-cell expression of unmutated IGHV 
Table 1: Molecular features of patients with 
progressive disease
Patients ID 
IGHV 
Homology
(%)
ZAP-70 
positive 
cells (%)
Patients with 
properties
200pts ≤98 ≤20 *
211pts ≤98 ≤20 *
221pts ≥98 ≥20 *
237pts ≥98 ≥20
242pts ≤98 ≤20 *
245pts ≥98 ≥20
251pts ≥98 ≤20 *
259pts ≤98 ≤20 *
265pts ≥98 ≥20 *
269pts ≥98 ≤20 *
408pts ≤98 ≤20 *
416pts ≤98 ≤20
422pts ≤98 ≤20 *
350pts ≤98 ≤20 *
352pts ≤98 ≤20 *
354pts ≥98 ≥20 *
356pts ≤98 ≤20 *
358pts ≤98 ≥20 *
360pts ≤98 ≤20
362pts ≤98 ≤20 *
364pts ≥98 ≥20 *
366pts ≥98 ≥20 *
368pts ≥98 ≥20 *
353pvs ≥98 ≥20
363pvs ≥98 ≥20
374pvs ≤98 ≤20 *
378pvs ≥98 ≥20 *
381pvs ≤98 ≥20 *
384pvs ≤98 ≤20 *
387pvs ≥98 ≥20 *
391pvs ≥98 ≥20 *
396pvs ≥98 ≥20 *
400pvs ≥98 ≤20 *
407pvs ≤98 ≤20 *
412pvs ≤98 ≤20 *
415pvs ≥98 ≥20 *
418pvs ≥98 ≥20 *
423pvs ≥98 ≤20 *
431pvs ≥98 ≥20 *
436pvs ≤98 ≤20
440pvs ≥98 ≥20 *
483pvs ≥98 ≥20 *
509pvs ≤98 ≤20
523pvs ≥98 ≥20
228pvs ≥98 ≥20 *
234pvs ≥98 ≥20
255pvs ≥98 ≤20 *
262apvs ≤98 ≤20 *
329pvs ≤98 ≤20
332pvs ≤98 ≤20
321pvs ≤98 ≤20 *
340pvs ≥98 ≥20 *
206pvs ≤98 ≥20 *
Blue labels indicate correct prediction of miR-181b 
expression and discordant  prognostic  markers IGHV 
/ZAP-70Oncotarget 2012; 3:  195-202 199 www.impactjournals.com/oncotarget
genes or ZAP-70).  Decline of 50% or more between 
sequential samples and/or value of ≤ 0.005 at the initial 
observation were noted in serial samples collected from 16 
patients that do not have CLL cells with high expression of 
ZAP-70 and unmutated IGHV, whereas only in 5 patients 
sequential samples were lacking in properties while CLL 
cells expressed high ZAP-70 and unmutated IGHV (Table 
1).  On the other hand, miR-181b was apparently worse 
predictor of the stable disease compared to the other 2 
prognostic markers, in that, among sequential specimens 
from this patient category, the properties were observed 
in 7 cases that have CLL cells with low expression of 
ZAP-70 and mutated IGHV, whereas only 3 cases did 
not showed the properties and had CLL cells with high 
expression of ZAP-70 and unmutated IGHV (Table 2). A 
further analysis of the data shows that the drop of miR-
181b that occurs in patients with a stable disease only in 
one case leads to a lowering of the miR expression level 
of ≤0.005, threshold that we set as low value in our study 
for patients with a progressive disease;  in all the other 
cases the expression of miR-181b decreases but stays 
still high.   We did not draw attention to this point in our 
study because the methodology we used to determine 
the expression of miR-181b is not absolute, but this is an 
important consideration that should be taken into account. 
This allow us to define miR-181b the most significant 
biomarker of progressive disease at least in the tested 
cohorts (Table 3 of [28]). 
Another point that needs to be discussed concerns the 
expression of miR-181b relative to the purity of the PBMC 
samples. The majority  of samples from patients with CLL 
used for our study were PBMCs with high content of 
CD5/CD19 positive cells; a few of them had a fraction 
of  leukemic  CD5/CD19 positive cells around 80% at the 
initial point. In serial samples from those patients miR-
181b  expression  reflects  the  same  trend  of  sequential 
specimens with high content of the leukemic clone at 
the initial observation.  This result make the prediction 
of the progression for this disorder easier, since hospital 
laboratories do not need to purify the CD5/CD19 positive 
Figure 2: Expression values of miR-181a and miR-181b in sequential samples from patients with progressive 
disease(training set). Relative expression of the mature miRNAs, in the first time point (dark blocks) and last time point (clear blocks) 
from sequential samples of CLL patients with progressive  disease. The expression has been determined by stem-loop qRT-PCR. Each 
sample data was normalized to the endogenous reference RNU44 by using 2-∆ct method. P value is the result of the paired ttestOncotarget 2012; 3:  195-202 200 www.impactjournals.com/oncotarget
cells; qRT-PCR to evaluate the expression of miR-181b 
can be easily performed on the RNA extracted from the 
total PBMC population. 
CONCLUSION 
There has been extensively evidence that miR-
181b is down-regulated in chronic lymphocytic 
leukemia compared to the normal control [18, 28, 
31].  In our study we demonstrated that its expression 
further decreases during the progression   of this 
disease, suggesting its evaluation as an important tool 
for monitoring the course of CLL. The miR-181b also 
has an important biological role in CLL, since it targets 
MCL1, TCL1, BCL2 and AID. It can be considered as 
one of the genes, such as NOTCH1, XPO1, MYD88 
or KLHL6, recently discovered to be important in this 
disease [32]. NOTCH1 has been found mutated in 
almost half of the patients with CLL B-cells carrying 
the trisomy 12 [33]. Moreover, conversely to IGHV 
mutational status and ZAP-70 expression, which are 
markers at the diagnosis, the expression levels of 
miR-181b can be evaluated in PBMC of patients over 
time, providing potential means to monitor for patients 
who imminently might require therapy. Therefore, our 
findings introduce a novel approach in the standard care 
of CLL patients that could benefit  either patients with 
increased risk of progression (ZAP70 +, unmutated 
IGHV status) or with favorable prognosis (ZAP70- and 
mutated IGHV status).
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